In a post-ASCO 2025 conversation, pharmaphorum web editor Nicole Raleigh spoke with Dr Pamela Tenaerts, chief medical officer at Medable, about the company’s new digital-first model to handle ...

Nevertheless, there are issues here, too, with long waiting lists, resource constraints, and patient strife when attempting to access treatments and consultations. There are even problems with rising ...

SCOPE is testing administration of intramuscular SCIB1 and intradermal iSCIB1+, which codes for various melanoma antigens ...

The FDA appears to have won its staring contest with Sarepta over shipments of Elevidys, after the company blinked and agreed ...

Sanofi has moved to bolster its vaccines business by reaching a deal to buy London, UK-based biotech Vicebio, which was ...

The UK is poised to become the first country in the world to launch a new payment model for antibiotics that could reverse decades of decline in the category.

As prescription drug abuse has grown in the US and Europe, the diversion of such treatments from legitimate sources has also increased. Ben Hargreaves speaks to an expert in the area to learn how ...

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections.

FDA Commissioner Dr Marty Makary. The FDA is moving at breakneck speed to roll out a generative artificial intelligence (AI) tool for speeding up regulatory reviews, announcing its launch nearly a ...

More than 30 years after it was first formed, Geron is on the cusp of bringing its first product to market, after imetelstat hit the mark in a phase 3 trial in patients with myelodysplastic ...

Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see its alliance shelved, just two and a half years after being set up.

Earlier this year, Bayer formed a new business unit that promised to shake up the consumer health category with a new personalised approach driven by digital technologies. Now, it has taken the ...